Several authors have already demonstrated its effect in patients with PIK3CA-related overgrowth syndromes or PIK3CA-altered lymphatic malformations, and as a result of the EPIK-P1 clinical study9, it has recently been approved by the FDA for adult and pediatric patients with severe manifestations of the PIK3CA-related overgrowth spectrum10–13. This evidence concerns the gene PIK3CA and lymphatic malformation.